RESEARCH MONOGRAPH · KDC-MN-307

Hydergine (Ergoloid Mesylates)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

59/100

The first nootropic in the modern sense, mostly historical now but the cerebrovascular and adrenergic mechanism is still interesting

Hydergine is the Sandoz product (Albert Hofmann's lab, before LSD) that brought ergoloid mesylates to market in 1949 as a cerebrovascular and cognitive intervention for elderly patients. It's a mixture of three dihydrogenated ergot alkaloids: dihydroergocornine, dihydroergocristine, and dihydroergokryptine (the last in alpha and beta forms), all in roughly equal proportions, all as methanesulfonate salts. So mechanistically it's a polypharmacological agent, not a single-target compound.

The pharmacology is multimodal. Alpha-1 adrenergic antagonism is the most prominent effect, with corresponding vasodilation and a meaningful reduction of systemic and cerebral vascular tone. Dopamine receptor effects (mostly D2 partial agonism), serotonin receptor activity (5-HT1, 5-HT2 binding profiles that vary across the constituent alkaloids), and various downstream effects on cyclic AMP signaling that contribute to the cognitive and cerebrovascular pharmacology. The dihydro modification (saturating the C9-C10 double bond) reduces the ergot-related vasoconstriction and increases the alpha-adrenergic antagonism over the parent ergot alkaloids.

The clinical evidence is mixed. Hydergine was widely used for dementia and cognitive impairment of vascular origin for forty years, with a lot of trial data but variable methodology. The Cochrane reviews and modern meta-analyses are generally lukewarm: probable small benefit in cognitive function in elderly patients with vascular cognitive impairment, but the effect size is modest and the methodology of the supporting literature is mostly pre-modern.

What we like: long clinical use history, multimodal cerebrovascular pharmacology that's mechanistically interesting, and a compound that helped establish the entire nootropic class. The Sandoz pharmacology work is genuinely substantial.

What we dont love is that hydergine has been mostly displaced clinically by the cholinesterase inhibitors for Alzheimer's-type dementia and by more targeted cerebrovascular agents for vascular indications. The polypharmacological profile is interesting as research but it's not what you'd design for a contemporary clinical program.

Sourcing is okay. Pharma-grade hydergine (ergoloid mesylates USP) exists in some markets, research-grade material is available, and the constituent ratio QC is the thing to confirm because the mixture proportions matter for the pharmacology. HPLC of the four constituent alkaloids is the appropriate QC. The compound is reasonably stable but light- and air-sensitive.

Evidence: 55
Mechanism: 65
Reliability: 55
Safety: 75
Sourcing: 65
Value: 60
Signal: 50
Staying power: 50

Plain-language summary Intrigue 38 / 100

Hydergine (ergoloid mesylates, codergocrine) is a 1940s drug developed at Sandoz by Albert Hofmann (the same chemist who synthesized LSD a few years earlier). It is a mixture of dihydrogenated ergot alkaloids and was once one of the most-prescribed drugs in the world for senile mental decline. The mechanism is messy and incompletely understood, involving alpha-adrenergic blockade, dopamine and serotonin modulation, and effects on neuronal energy metabolism. Modern clinical trials in dementia produced mostly disappointing results, and prescribing collapsed from the 1990s onward. It survives in nootropic communities as a heritage smart drug. Of mainly historical interest. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Ergoloid mixture (dihydroergocornine, dihydroergocristine, dihydroergocryptine)

A mixture of dihydrogenated ergoloid alkaloids; used historically for cognitive decline and as a senescence-associated nootropic.

Abstract

Hydergine (codergocrine mesylate; CAS 8067-24-1; mixture of dihydroergocornine, dihydroergocristine, and dihydroergocryptine alpha and beta isomers in 3:3:2:1 ratio; molecular weight approximately 660 to 700 Da) is a mixture of dihydrogenated ergoloid alkaloids developed at Sandoz (now Novartis) by Albert Hofmann in the 1940s. The compound was approved for senescence and senile mental status in many countries from the 1950s onward; it was once among the most prescribed drugs globally. Mechanism is multifactorial and incompletely characterized: alpha-adrenergic antagonism, dopaminergic and serotonergic effects, modulation of neuronal energy metabolism, and weak antioxidant activity. Modern systematic reviews have produced inconsistent evidence of cognitive benefit; the compound is largely supplanted in clinical practice by cholinesterase inhibitors and memantine for dementia. Plasma half-life is approximately 5 hours. Used as a historical nootropic and ergoloid reference compound.

Mechanism of action

Multifactorial: alpha-adrenergic antagonism, dopaminergic/serotonergic modulation, neuronal energy effects. Mixture of dihydrogenated ergoloid alkaloids.

Reported research dose ranges

Clinical 4.5 to 9 mg in the published literature.

References

Schneider LS, Olin JT. Overview of clinical trials of hydergine in dementia. Arch Neurol 1994.
Olin J, Schneider L, et al. Hydergine for dementia. Cochrane Database Syst Rev 2001.
Crook T. The pharmacotherapy of memory disorders. Drugs Aging 1990.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-307

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Hydergine (Ergoloid Mesylates)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs